Historical Archive

Drugs: AIFA launches the maneuver

New 'maneuver' to contain pharmaceutical expenditure. The AIFA Board of Directors yesterday approved measures for companies to 'recover' around 388 million euros. Objective: to make up for the breach of the expenditure ceiling programmed for 2005 and that relating to the first three months of 2006.
Added to this figure is the 'savings' effect of generic-equivalent medicines (estimated at 60 million). The Board - reports a note - has given a mandate to the AIFA General Management to issue the relative provision by 15 July. The containment measures not only make up for the breach of the 2005 spending ceiling, but also contain 2006 spending.
In fact, “a further temporary reduction in the price of drugs, however dispensed or used by the NHS, from the current 4.4% to 5% is envisaged, confirming the exclusions already provided for in the previous provision of 30 December 2005. This reduction makes it possible to completely and the definitive way - AIFA specifies - the breakthrough of the pharmaceutical expenditure ceiling programmed for 2005, for the share of the 60% to be paid by private subjects".

The Board has also decided “a maneuver to revise the National Pharmaceutical Handbook (Pfn) which provides for a selective and temporary reduction in the price of medicines up to a maximum of 12% and until the part under its responsibility is recovered. This maneuver - explains the note - refers to medicines which in the first quarter of 2006 recorded an increase above the sector average, without there being a justified reason on an epidemiological level; and in any case this corresponds to a necessary rebalancing between expenditure and consumption”. “The selectivity of the Prontuary revision provision – reads the AIFA note – concerns 502 packs out of 4799 (equal to 10.5%) and refers to 98 companies out of the 374 operating on the national territory (26.4%).

The provisions of the BoD, in ensuring a government of expenditure consistent with the planned economic availability, were taken within an overall platform aimed at ensuring at the same time the governance and development of the pharmaceutical sector. In this regard – concludes the press release – AIFA renews its commitment to the pharmaceutical sector and to each individual company, to guarantee the conditions for investment in research and development in the pharmaceutical sector in Italy”.


Articoli correlati

Back to top button
Fedaiisf Federazione delle Associazioni Italiane degli Informatori Scientifici del Farmaco e del Parafarmaco